Lotte De Wever, Caitlin Goemaere, Giorgio Peroni, Chandra Widyananda Winardhi, Matthieu Nicolaas Boone, Veerle Cnudde, Ludwig Cardon, Chris Vervaet, Valérie Vanhoorne
[ Int. J.Pharm. 2025, 686, 126271; https://doi.org/10.1016/j.ijpharm.2025.126271 ]
Fused Filament Fabrication (FFF) requires filaments with specific mechanical and physical properties, limiting formulation flexibility. Pellets could be used as feedstock material for direct extrusion additive manufacturing (DEAM) where a conventional filament printing head is replaced by a single-screw extrusion unit. Brittle filaments containing 60% anhydrous theophylline and 40% Soluplus® (m/m) were prepared via hot melt extrusion and shredded into pellets. A full factorial screening design evaluated the impact of four printing parameters (print temperature, infill, overlap and extrusion multiplier) on critical quality attributes of the 3D printed tablets, including tablet mass, content uniformity, drug degradation, mechanical properties, dissolution, dimensions, and porosity. The extrusion multiplier was identified as a new key process parameter, enabling personalized medicine by tailoring dose, porosity and dissolution profiles.







